Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 1/2012

Open Access 01-12-2012 | Oral presentation

From discovery of RANKL to clinical application of anti-human RANKL antibody

Authors: Hisataka Yasuda, Yuriko Furuya, Kohji Uchida

Published in: Arthritis Research & Therapy | Special Issue 1/2012

Login to get access

Excerpt

Osteoporosis is a common bone disease characterized by reduced bone and increased risk of fracture. In postmenopausal women osteoporosis results from bone loss attributable to estrogen deficiency. Receptor activator of nuclear factor-B ligand (RANKL) is a pivotal osteoclast differentiation factor [1]. Discovery of RANKL has opened a new era in the understanding of mechanisms in osteoclast differentiation over the last decade. The discovery also results in the development of a fully human anti-RANKL neutralizing monoclonal antibody (called denosumab) and denosumab has been approved for the treatment of osteoporosis in Europe and the US. …
Literature
1.
Yasuda H, Shima N, Nakagawa N, et al: Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 1998, 95: 3597-3602. 10.1073/pnas.95.7.3597.PubMedCentralCrossRefPubMed
2.
Tomimori Y, Mori K, Koide M, et al: Evaluation of pharmaceuticals with a novel 50-hour animal model of bone loss. J Bone Miner Res. 2009, 24: 1194-1205. 10.1359/jbmr.090217.CrossRefPubMed
3.
Furuya Y, Mori K, Ninomiya T, et al: Increased bone mass in mice after a single injection of an anti-RANKL neutralizing antibody: evidence for a bone anabolic effect of PTH in mice with few osteoclasts. J Biol Chem. 2011,
4.
Kostenuik PJ, Nguyen HQ, McCabe J, et al: Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res. 2009, 24: 182-195. 10.1359/jbmr.081112.CrossRefPubMed
Metadata
Title
From discovery of RANKL to clinical application of anti-human RANKL antibody
Authors
Hisataka Yasuda
Yuriko Furuya
Kohji Uchida
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue Special Issue 1/2012
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar3588

Other articles of this Special Issue 1/2012

Arthritis Research & Therapy 1/2012 Go to the issue

Poster presentation

Fas deficiency attenuates bone loss during antigen induced arthritis in mice

Poster presentation

Combined depletion of interleukin-1 and interleukin-6 does not exceed single depletion of interleukin -1 in TNF-mediated arthritis

Oral presentation

Cancer immunotherapy; integration of T cell biology with nanogel- and vector-technology in translational research

Poster presentation

Intermittent cold stress-induced experimental fibromyalgia model in mice - pharmacology and neurobiology

Oral presentation

Skeletal involvement in the pathogenesis and outcomes of rheumatoid arthritis and osteoarthritis

Oral presentation

Synovial fibroblasts display an uncontrolled inflammatory and tissue destructive response to TNF-α
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits